Keros Q1 net loss widens to $43.1M; cash $442.4M, runway into 2027

Keros Therapeutics, Inc.

2024-Q1 EPS reported -$1.21

Net loss of $43.1M in Q1 2024 vs $35.8M in Q1 2023, driven by higher R&D spending.
R&D expenses $38.3M (up $7.2M YoY) reflecting pipeline advancement and manufacturing.
Cash and equivalents $442.4M as of March 31, up from $331.1M at year-end.
KER-050 Phase 3 MDS trial design discussed with FDA; update expected mid-2024.
KER-012 TROPOS Phase 2 PAH trial update anticipated in Q2 2024; ATS poster in May.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Keros Therapeutics, Inc. reported quarter ended March 31, 2024 results: net income net loss of $43.1 million.

Period: quarter ended March 31, 2024
Net income: net loss of $43.1 million
Result: reported results

Exact text from the filing

Keros reported a net loss of $43.1 million in the first quarter of 2024 as compared to a net loss of $35.8 million in the first quarter of 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-24-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.